NIH, Gates Foundation commit $200M to cure HIV, sickle cell

Francis Collins - NIH Director
Francis Collins, NIH director (National Institutes of Health)

The National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation have each committed $100 million to advance cures for HIV and sickle cell disease. The goal is to start testing in vivo gene-based treatments for the diseases in humans within 10 years and ultimately to make them available at a cost that enables global use.

President Donald Trump moved the eradication of HIV in the U.S. up the agenda earlier this year, leading to 2020 budget proposals that carve out money for tackling the disease. The NIH has responded to the call to wipe out HIV by committing to spend $100 million over the next four years and enlisting the Gates Foundation to match the commitment.

The plan set out by the NIH and Gates Foundation expands on Trump’s proposal, most notably by adding sickle cell disease to the agenda. Sickle cell differs from HIV in many ways, not least the fact that it is a genetic, not infectious, disease, but the NIH sees important overlaps.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

In both diseases, the NIH and Gates Foundation plan to pursue the same gene-based strategies. The NIH listed vector tropism and efficiency, gene targeting and in vivo delivery as the shared strategies.

The focus on in vivo delivery is key to the NIH and Gates Foundation’s long-term plans. Vertex Pharmaceuticals and CRISPR Therapeutics already have a gene-based treatment for sickle cell in the clinic. However, the gene editing takes place outside of the body, meaning cells must be taken from a patient, modified and readministered back into the same individual.

That is an expensive, logistically challenging process in the U.S. At best, the resulting therapies would be too expensive to deploy across sub-Saharan Africa, as the NIH and Gates Foundation envisage. At worst, it would be logistically impossible to produce the therapies in sub-Saharan Africa at all.

Those factors make in vivo treatments a better choice, but the science of editing DNA within the body is immature. Armed with $200 million, the NIH and Gates Foundation aim to change that, for example by identifying ways to selectively modify genes in hematopoietic stem cells. 

The money will fund efforts to identify potential cures for both diseases for preclinical and clinical testing. Beyond that, the partners want to ally with organizations in Africa to collaborate on getting drugs into late-phase development. The NIH wants trials to be underway in the U.S and sub-Saharan Africa within seven to 10 years. 

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.